On September 13th, 2023, Porton Advanced Solutions (Porton Advanced) announced a strategic partnership with BRL Medicine Inc. (BRL Medicine). This collaboration will enhance the cell and gene therapy pipelines from BRL Medicine from clinical trials to further expedite the commercialization of innovative therapies.
BRL Medicine, with its strong gene editing technology, robust R&D capabilities, and prospective pipelines, has been devoted to the realm of CGT for years and has achieved significant progress. Multiple pipelines of the company have entered the IND application stage, with three core ones already receiving China IND approval. The gene therapy product, BRL-101, was developed using the in-house ModiHSC® hematopoietic stem cell platform. Whereas, the CAR-T product, BRL-201, was developed using the in-house non-viral site-specific integration CAR-T platform (Quikin CART®). Notably, both have shown impressive results in clinical trials, gaining recognition from prestigious international academic journals like Nature and Nature Medicine.
Porton Advanced, on the other hand, has built an end-to-end gene and cell therapy CDMO service platform with proven experience in plasmids, cell therapy, gene therapy, oncolytic viruses, mRNA therapy, and bacterial therapy. Through this strategic partnership, the two companies will work together to accelerate the commercialization of gene and cell therapy drugs, making innovative treatments accessible to a wider range of patients.
About Porton Advanced
Porton Advanced is a subsidiary of the globally recognized CDMO Porton Pharma Solutions Ltd. (SZSE Stock Code 300363), founded in 2018. Located in Suzhou, China, Porton Advanced offers a cGMP-compliant manufacturing platform for plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy, enabling different development stages for global companies.
Porton Advanced operates on a "Customer First" approach to Gene and Cell Therapeutics (GCT) manufacturing, anchored by its core principles of "Compliance, Expertise, and Open Collaboration". The company operates to rigorous, internationally harmonized Quality Management and IP protection standards, bringing innovative manufacturing solutions to the complex challenges in the GCT space.
